Healthcare · Automotive
Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard of care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer
Patient-reported outcomes from phase III lidERA study showed improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer
Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours
Basel, 19 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) will present new data, including two late-breaking abstracts, across lung, breast and other cancers at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting, held from 23 to 27 October in Madrid.
“Our presentations at ESMO 2026 highlight the depth and impact of Roche’s oncology pipeline, driven by emerging science capable of bringing new treatment benefits across diverse and high-unmet-need cancers,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “From establishing head-to-head superiority with divarasib in KRAS G12C-mutated lung cancer to advancing patient-centered oral SERD therapies like giredestrant and next-generation ADCs such as Tam-Peli, we are committed to delivering medicines that not only extend life, but also seek to improve treatment experience, tolerability and quality of life for people living with cancer.
Divarasib demonstrated superior efficacy and best-in-class potential in KRAS G12C NSCLC
Roche will share phase III Krascendo 1 results, which demonstrated divarasib’s best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer.
Krascendo 1 is the only global head-to-head trial to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation inhibitors.1
Results for this potential best-in-class, next-generation KRAS G12C-targeted therapy will be presented as a late-breaking abstract during a Presidential Symposium.
Giredestrant data support its potential to become the new standard of care in early-stage and advanced breast cancer
Roche will present new data highlighting the potential role of giredestrant, an investigational, oral, potent next-generation selective oestrogen receptor degrader (SERD) and full antagonist,2 in oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, a subtype in which more than 90% of cases are diagnosed at an early-stage (I-III).3-6 Key presentations from early-stage to advanced disease include:
Patient-reported outcomes from the phase III lidERA Breast Cancer trial suggesting that the improved efficacy of giredestrant compared to endocrine therapy is achieved without compromising tolerability or Health-Related Quality of Life.
Exploratory biomarker findings from the evERA Breast Cancer trial of giredestrant in combination with everolimus in ER-positive, HER2-negative advanced breast cancer in the post-cyclin-dependent kinase 4/6 inhibitor setting.
Updated interim results for giredestrant plus inavolisib from the MORPHEUS Breast Cancer trial evaluating giredestrant treatment combinations in ER-positive, HER2-negative locally advanced or metastatic breast cancer.
Data demonstrate the potential of a next generation B7-H3 targeted antibody-drug conjugate (ADC) Tam-Peli (tambotatug pelitecan)
New data will also be presented for Tam-Peli, an investigational next generation B7-H3-targeted ADC designed to deliver high-potency anti-tumour activity while limiting off-target toxicity.7 Tam-Peli is currently being investigated across multiple solid tumour indications:
ESMO data include late-breaking interim phase III results in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma, analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies, and phase I efficacy and safety data for Tam-Peli in patients with locally advanced or metastatic NSCLC.
These findings build on the TAISHAN-302 phase III data in second-line small cell lung cancer presented at the World Conference on Lung Cancer in September, where the study met all three specified endpoints of overall survival, progression free survival and objective response rate at its first interim analysis.
Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau, and plans to rapidly initiate global trials across multiple tumour types.
Overview of key presentations featuring Roche medicines and molecules:
Medicine or moleculeAbstract titleAbstract number/ presentation details
Lung cancer
DivarasibKrascendo 1: Efficacy and safety of divarasib (diva) vs sotorasib (soto) or adagrasib (ada) in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC.#LBA5 Proffered Paper Session
Presidential Symposium II
Sunday 25.10.2026
16:30 - 16:42 CET
DivarasibKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer. #2551 TiP Poster
NSCLC, Early-Stage
Monday 26.10.2026
12:00 – 12:45 CET
Tam-PeliTambotatug pelitecan (YL201): Efficacy and safety in locally advanced/ metastatic NSCLC from a phase I study. #2577 Poster
NSCLC, Locally Advanced
Monday 26.10.2026
12:00 – 12:45 CET
Non-specificImmunogenomic signature associated with ICI-related pneumonitis in non-small-cell lung cancer (NSCLC) patients.#4247 Rapid Oral
Basic Science and Translational Research
Sunday 25.10.2026
09:14 - 09:19 CET
Breast cancer
GiredestrantPatient (pt)-reported outcomes (PROs) from the phase III lidERA Breast Cancer (BC) trial of giredestrant (GIRE) in pts with oestrogen receptor-positive, HER2-negative early BC (ER+, HER2− eBC). #538 Rapid Oral
Breast Cancer, Early-Stage
Friday 23.10.2026
16:20 – 16:25 CEST
GiredestrantRetrospective exploratory biomarker (BM) analyses from evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients with oestrogen receptor-positive, HER2-negative advanced BC (ER+, HER2− aBC) in the post-CDK4/6 inhibitor (I) setting.#2 Rapid Oral
Breast Cancer, Advanced Stage
Saturday 24.10.2026
10:20 – 10:25 CEST
GiredestrantUpdated interim analysis of giredestrant (GIRE) + inavolisib (INAVO) in MORPHEUS Breast Cancer (BC): A phase Ib/II study of GIRE treatment (tx) combinations in patients (pts) with oestrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2− LA/mBC).#23 Poster
Advanced Breast Cancer, Other
Saturday 24.10.2026
12:00 – 12:45 CEST
PertuzumabReal-world eligibility for DESTINY-Breast11 (DB-11) neoadjuvant escalation criteria and outcomes of DB-11-eligible vs DB-11-ineligible patients with HER2-positive early breast cancer (HER2+ eBC).#594 Poster
Breast Cancer, Early-Stage
Saturday 24.10.2026
12:00 – 12:45 CEST
ZN-1041BREnnA: Phase II/III randomised study of ZN-A-1041 or tucatinib (TUC), in combination with trastuzumab + capecitabine (HX), in patients with HER2-positive locally advanced or metastatic breast cancer (HER2+LA/mBC) with or without central nervous system (CNS) metastases. #1796 TiP Poster
HER2+ Breast Cancer
Saturday 24.10.2026
12:00 – 12:45 CEST
Solid tumours
Tam-Peli
Tambotatug pelitecan (YL201): Analyses of interstitial lung disease in patients with advanced solid tumours from phase I/II studies. #1057 Poster
Developmental Therapeutics
Friday 23.10.2026
15:15 – 16:00 CEST
YL211 (cMET ADC)Phase I First-in-Human (FIH) Results of YL211, a c-Met targeting Antibody-Drug Conjugate (ADC), in patients (pts) with advanced solid tumors.#1017 Poster
Developmental Therapeutics
Friday 23.10.2026
15:15 – 16:00 CEST
Tam-Peli
Tam-Peli versus chemotherapy in heavily pretreated recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): a multicenter, randomised, open-label, phase III study (TAISHAN-301).#LBA43 Proffered Paper Session
Head and Neck Cancer
Sunday 25.10.2026
08:40 - 08:50 CET
Tecentriq (atezolizumab) + Avastin (bevacizumab)Outcomes by baseline tumor burden using 6-and-12 scores and the up-to-7 criteria in TALENTACE: phase III study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo/Bev) or on demand TACE alone in patients with systemically untreated, unresectable hepatocellular carcinoma (uHCC). #1700 ePoster
Hepatocellular Carcinoma
Tecentriq (atezolizumab)ATOMIC (A021502/AIO-KRK-0317): Presentation and outcomes in patients (pts) with stage III d-MMR early-onset colon cancer (EOCC) and average-onset colon cancer (AOCC).#858 Poster
Colon Cancer
Sunday 25.10.2026
12:00 - 12:45 CET
Tecentriq (atezolizumab)Adjuvant atezolizumab in patients with MSI-high/MMR-deficient stage III colorectal cancer ineligible for oxaliplatin-based chemotherapy: the phase II ANTONIO-study (AIO-KRK-0220).#802 Poster
Colon Cancer
Sunday 25.10.2026
12:00 - 12:45 CET
About Roche in Oncology
For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Gadgeel S, et al. P3.12D.07 Divarasib Versus Adagrasib or Sotorasib in Pretreated KRAS G12C+ Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). J of Thorac Oncol. 2024; 19 (10, Supplement): S349.
[2] Martin M, et al. Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Presented at: ESMO Annual Meeting; 2022 September 9-13; Paris, France. Abstract #211MO.
[3] F. Hoffmann‑La Roche Ltd. (2026) SEER Explorer All BCa by Stage. Data on file.
[4] F. Hoffmann‑La Roche Ltd. (2026) Stage Distribution. Data on file.
[5] F. Hoffmann‑La Roche Ltd. (2026) KREBS and TRM. Data on file.
[6] F. Hoffmann‑La Roche Ltd. (2026). UK_CRUK_EDHub_IncidenceByStageRCRD_DataTable2026-01-08. Data on file.
[7] Xu J, et al. Cancer Res. 2023;83:6304.
Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com
Tristan Schmitz
Phone: +41 79 529 70 35Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone: +41 79 377 83 75Albert Thottiyil
Phone: +41 79 775 66 12
Roche Investor Relations
Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Attachment
Media&Investor Release Roche ESMO 2026 English
Oct 19 · 05:00·Roche
Finance · Crypto
LAKE MARY, Fla., October 18, 2026 - OpenWorld, Inc. (“OpenWorld” or the “Company”) (NASDAQ: OPNW), an innovation company advancing global real-world asset (“RWA”) tokenization, today announced the signing of a definitive merger agreement to acquire Blocksight and outlined how its acquisition of Blocksight Holdings Co. (“Blocksight”), announced on October 1, 2026, is intended to serve as the operating foundation for the Company’s tokenized financing programs in infrastructure and energy. Blocksight builds AI agents that bring real-world assets on-chain, automating deal structuring, asset data verification, investor onboarding, daily investor reporting and ongoing investment servicing, with human approval required at key decision points. Upon completion of the acquisition, these agents are expected to be integrated into OpenWorld Enterprise, the platform through which OpenWorld structures, administers and reports on tokenized RWA programs.
In the two weeks since the Blocksight announcement, OpenWorld has announced two tokenized financing programs that OpenWorld Enterprise is expected to structure and service. On October 7, 2026, the Company entered into a non-binding term sheet with BeyondAI for a proposed intellectual property-backed transaction of up to $130 million, under which digital tokens would represent investors’ rights to payments backed by eligible BeyondAI intellectual property. On October 15, 2026, the Company entered into a non-binding term sheet with Meridian to establish a tokenized financing program of up to $1 billion to fund a distributed AI computing network powered by on-site solar energy and residential battery storage, with an expected initial deployment planned for 10,000 homes. Together, the three announcements describe a single model: one platform, one agentic workflow, applied across asset classes.
Key Highlights
One platform, one repeatable model: OpenWorld Enterprise is the structuring, administration and reporting layer for each program. Blocksight’s agents are intended to become the orchestration layer inside that platform, so that each new program reuses the same verification, onboarding and reporting infrastructure rather than rebuilding it.
Agentic workflow with human approval: Blocksight’s agents are expected to cover five stages of a tokenized financing: deal structuring, asset data verification, investor onboarding, daily investor reporting and ongoing servicing. People approve the decisions that matter at each stage.
Applied to intellectual property (BeyondAI): In an IP-backed structure, the agents are expected to verify eligible patents and software rights, onboard investors and report daily on the payment streams that back the tokens, while BeyondAI retains control of its technology.
Applied to energy and computing infrastructure (Meridian): In a distributed network of residential battery storage, solar panels and AI computing equipment across thousands of properties, the agents are expected to ingest equipment performance data via IOT devices, reconcile hosting payments and AI inference revenue, and deliver investor reporting on the underlying assets.
Team: The Blocksight co-founders Patrick Kim and Peter Hong are expected to join OpenWorld upon closing of the merger.
“We want to build a model in which the Blocksight acquisition provides the foundation for our tokenization work in infrastructure and energy,” said Matt Shaw, CEO of OpenWorld. “We expect our proposed transaction with BeyondAI to demonstrate that industrial AI intellectual property can be structured as financeable collateral. Our term sheet with Meridian extends that same model to physical assets: Tesla Powerwall residential battery storage, solar generation and AI compute nodes across thousands of properties. Programs of that size cannot be verified, onboarded and reported on by hand. Blocksight’s agents are how we intend to do it at scale, with people approving every decision that matters.”
From Transaction to Platform
Tokenizing a real-world asset is not a single event. Each program requires the underlying assets to be structured into a financeable form, the data behind those assets to be verified, investors to be onboarded and documented, performance to be reported on a continuing basis, and payments to be serviced over the life of the structure. Performed manually, each of these steps limits how many programs a platform can run and how large each program can be.
Blocksight was built to automate that lifecycle. Its agents structure deals, verify asset data, onboard investors, produce daily investor reporting and service investments on an ongoing basis, with humans required for key decisions. After the closing of the merger, OpenWorld intends to make this workflow the standard operating layer of OpenWorld Enterprise, so that the Company can take on larger programs, across more asset classes, with consistent verification and reporting for investors.
Applying the Model: BeyondAI
Under the October 7, 2026 term sheet, OpenWorld would provide transaction structuring, tokenization, technology integration, reporting infrastructure and operational services for a proposed IP-backed transaction of up to $130 million. Each token would represent an investor’s rights to payments backed by eligible BeyondAI intellectual property, such as patents and software rights. The proposed arrangement is a financing backed by IP rights, not a sale of BeyondAI’s technology, and BeyondAI would retain control of its technology.
Within this structure, Blocksight’s agents are expected to support the verification of eligible intellectual property, the onboarding of investors and the daily reporting on the payment streams that back the tokens.
Applying the Model: Meridian
Under the October 15, 2026 term sheet, OpenWorld would serve as advisor, structuring agent and services provider for a tokenized financing program of up to $1 billion, and OpenWorld Enterprise would finance and operate the orchestration of a distributed AI computing network. Meridian holds purchase rights to Tesla Powerwall residential battery storage systems for the program and would own the storage assets within the structure. Residential battery storage, solar panels and AI computing equipment form the asset base. The initial deployment is planned for 10,000 homes, with larger installations at local schools, hospitals and commercial campuses. Initial installations are scheduled to begin in the fourth quarter of 2026, with the first commercial site targeted for the first quarter of 2027.
A program of this kind produces a continuous stream of operating data from thousands of sites: equipment performance, energy generated and stored, computing capacity delivered to AI inference providers, and payments owed to participating hosts. Blocksight’s agents are expected to ingest that data, reconcile it against the financing structure and provide investors with reporting on the underlying assets through OpenWorld Enterprise.
Transaction Status
The term sheets with BeyondAI and Meridian are non-binding, except for the provisions expressly stated to be binding, and each proposed transaction remains subject to the completion of confirmatory due diligence, negotiation and execution of definitive documentation, satisfaction of applicable conditions and completion of the contemplated transaction. In addition, the acquisition of Blocksight remains subject to the satisfaction or waiver of customary closing conditions. There can be no assurance that any of these transactions will be consummated on the terms described or at all.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “believes,” “continue,” “expect,” “plan,” “could,” “contemplate,” “may,” “will,” “should,” “would,” “intend,” “potential,” “designed,” and other words of similar meaning. Examples of forward-looking statements include, among others, statements regarding the acquisition of Blocksight, whether the OpenWorld Board of Directors will approve the acquisition, whether definitive transaction documentation will be executed, the anticipated timing, structure and benefits of the acquisition, the satisfaction or waiver of any closing conditions, the integration of Blocksight and its technology into OpenWorld Enterprise, the expected roles of Blocksight’s founders following closing, the integration of Blocksight’s technology into OpenWorld Enterprise, the proposed transactions with BeyondAI and Meridian, and the size, timing and structure of those programs and the ability of OpenWorld to realize the anticipated strategic and operational benefits of the proposed acquisition and proposed transactions. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on OpenWorld’s current beliefs, expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside OpenWorld’s control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not place undue reliance on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, the following: (1) the possibility that the OpenWorld Board of Directors does not approve the proposed transactions that the parties do not execute definitive transaction documentation; (2) the occurrence of any event, change or other circumstance that could cause the proposed transactions not to be completed, including the failure to obtain any necessary approvals or satisfy or waive applicable closing conditions; (3) the institution or outcome of any legal proceedings that may be instituted against OpenWorld, Blocksight, Meridian or BeyondAI following the announcement of the proposed transactions; (4) the risk that the proposed transactions disrupts current plans and operations as a result of the time it diverts from management; (5) OpenWorld’s ability to realize the anticipated benefits of the proposed transactions and successfully integrate Blocksight’s, Meridian or BeyondAI’s business, personnel and technology if the transactions are completed; (6) the risk that tokenized securities may face increased regulatory scrutiny and may not be broadly accepted by the market; (7) costs related to the proposed transaction; (8) changes in applicable laws or regulations; and (9) the risks and uncertainties described in OpenWorld’s Annual Report and Quarterly Reports filed with the SEC, including under the heading titled “Risk Factors.”
OpenWorld cautions investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read OpenWorld’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements speak only as of the date of this press release, and OpenWorld undertakes no obligation to update or revise any of these statements except as required by applicable law. OpenWorld’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should consider these risks and uncertainties. OpenWorld does not give any assurance that definitive transaction documentation relating to the acquisition of Blocksight or the proposed transactions with Meridian and BeyondAI will be executed, that the acquisition or transactions will be completed or that OpenWorld will achieve its expectations and objectives, financial or otherwise, even if the proposed acquisition or transactions are completed.
About OpenWorld
OpenWorld, Inc. (NASDAQ: OPNW) is a technology-powered digital assets and blockchain innovation company that co-architects and takes principal positions in enterprise blockchain initiatives alongside sovereign governments, institutional partners and major enterprises. Since its founding in 2023, OpenWorld has advised on projects representing over $66 billion in aggregate network value and supported more than 20 companies backed by leading global venture firms, including a16z, Multicoin Capital, Dragonfly and Founders Fund. OpenWorld’s capabilities span real-world asset tokenization, stablecoin infrastructure, capital markets advisory, governance structuring and public markets strategy, with active engagements across the United States, Gulf, Europe, Southeast Asia and Africa. To learn more, visit openworld.dev and follow OpenWorld on X at @_openworld.
About Blocksight
Blocksight Holdings Co. builds AI agents that bring real-world assets on-chain. Its agents automate deal structuring, asset data verification, investor onboarding, daily investor reporting and ongoing investment servicing, with human approval required at key decisions. Blocksight was co-founded by Patrick Kim and Peter Hong.
Investors:
ir@openworld.dev
Media:
Gasthalter & Co.
Phone: (212) 257-4170
Email: openworld@gasthalter.com
Oct 19 · 00:00·ACN Newswire